API | rg-2833

rg-2833 Report issue

Small molecule Experimental

Active Ingredient History

RG2833 is a compound originally developed by the Scripps Insitute for the treatment of Friedrick's Ataxia. RG2833 is a potent and selective inhibitor of neuronal histone deacetylase. RG2833 has been granted orphan drug status has been investigated in phase one clinical trials. There has also been proof of concept studies conducted for the treatment of Parkinson's disease. ^NCATS

Chemistry

SMILES: CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N
InChIKey: VOPDXHFYDJAYNS-UHFFFAOYSA-N
Mol. Mass: 339.4314
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Friedreich Ataxia (Phase 1)

Parkinson Disease ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue